Martin Vogelbaum
Martin Vogelbaum
Partner
“Working with great entrepreneur and emerging companies is what the venture capital business is all about. Having been a successful entrepreneur, I understand what it takes to build a company from start-to to exit. As a VC, I look for the next generation of thinkers who have the rare ability convert ideas into groundbreaking companies.”
Martin Vogelbaum is a partner at Rho.
He has more than 20 years of experience investing in the life sciences sector, having been involved with companies at all stages of development, including co-founding more than a half dozen companies. He joined Rho in 2005 and primarily focuses on investments in biotechnology, biopharmaceuticals and medical devices.
Prior to Rho, he was a partner of Apple Tree Partners, a life sciences venture firm focused on early-stage companies. While at Apple Tree, Martin co-founded four start-ups, including Gloucester Pharmaceuticals where he served as interim CEO and chairman. Martin began his venture capital career in 1993 at Oxford Bioscience Partners, where he served as a general partner. Prior to Oxford, he was a research associate in the bone marrow transplantation unit at Memorial-Sloan Kettering Hospital, where he conducted research in graft-versus-host-disease (GVHD).
Martin received his A.B. in biology and history from Columbia University.
-
Cara Therapeutics
Mersana
-
Aquesys
Gloucester Pharmaceuticals (acq. by Celgene)
SARcode Bioscience (acq. by Shire Pharaceuticals)